AAV-SLB111

AAV-SLB111 is an investigational engineered adeno-associated virus capsid developed by Solid Biosciences as part of its muscle-targeted vector platform for systemic gene delivery. Publicly available information indicates it is a modified AAV9-derived capsid candidate identified alongside related capsids such as AAV-SLB101 and AAV-SLB102, with reported in vitro properties including muscle-cell binding, uptake, and support of microdystrophin expression in assay systems used for Duchenne muscular dystrophy research. Based on the available evidence, AAV-SLB111 appears to function primarily as a **gene therapy delivery vector** rather than a fully characterized stand-alone therapeutic product, and the specific therapeutic transgene, clinical program, route, and disease-specific development path for AAV-SLB111 itself have not been clearly established in public sources.